Vaccines (Sep 2022)

Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices

  • Nina Geiger,
  • Eva-Maria König,
  • Heike Oberwinkler,
  • Valeria Roll,
  • Viktoria Diesendorf,
  • Sofie Fähr,
  • Helena Obernolte,
  • Katherina Sewald,
  • Sabine Wronski,
  • Maria Steinke,
  • Jochen Bodem

DOI
https://doi.org/10.3390/vaccines10101619
Journal volume & issue
Vol. 10, no. 10
p. 1619

Abstract

Read online

Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.

Keywords